PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial (PIONA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01192035|
Recruitment Status : Completed
First Posted : August 31, 2010
Last Update Posted : June 25, 2015
BACKGROUND: Since 1996 the combination of three or more drugs has been the mainstay of human immunodeficiency virus (HIV) treatment. The most important types of drugs are called nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) Response to treatment is measured as increasing CD4+ cell count and decreasing HIV viral load. A major problem is the development of resistance. NNRTIs are recommended as part of first-line treatment of HIV in Africa but many Africans have a slower NNRTI clearance than Caucasians making them more susceptible for development of resistance in case of treatment interruptions. PIs might therefore be a better option in an African setting with low adherence.
AIM: To evaluate two different treatment regimens in HIV-1 infected patients:
A) A NNRTI (efavirenz/nevirapine) based regimen and B) A PI (ritonavir-boosted lopinavir) based regimen with regard to treatment outcomes. HYPOTHESIS: Treatment with a PI will be superior to treatment with a NNRTI due to less development of resistance.
METHODS: Treatment-naïve adult HIV-1 patients enrolled in an existing cohort The West African Retrovirus and Acquired Immune Deficiency (WARAID) cohort in Guinea Bissau with CD4+ cell count ≤ 350 cells/µL and/or clinical signs of immune suppression (World Health Organization (WHO) clinical stage 3 or 4) will be randomised 1:1 to: Treatment A: 2 NRTIs (lamivudine and either zidovudine or stavudine) and 1 NNRTI (efavirenz or nevirapine) or Treatment B: 2 NRTIs (same as in treatment A) and 1 PI (ritonavir-boosted lopinavir). Primary outcome: Viral load suppression <400 copies/ml 12 months after enrolment.
PERSPECTIVES: Guidelines for treatment of HIV in Africa are more or less a copy of the guidelines used in Europe and North America. Genetic differences in pharmacokinetics, more women infected in Africa and difficulties ensuring good adherence mean that results obtained from Caucasian patients are not directly transferrable to African patients. The results of this study will hopefully help guiding the treatment of HIV in Africa in the future. The investigators believe the HIV infected people in West Africa deserve the same evidence-based medicine as in developed countries.
|Condition or disease||Intervention/treatment||Phase|
|HIV-1||Drug: Efavirenz or Nevirapine Drug: Ritonavir-boosted lopinavir||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial|
|Study Start Date :||May 2011|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||September 2014|
|Active Comparator: NNRTI||
Drug: Efavirenz or Nevirapine
2 NRTIs (lamivudine 150 mg "bis in die - twice a day" (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg "omne in die - once daily" (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz.
|Active Comparator: Protease inhibitor||
Drug: Ritonavir-boosted lopinavir
2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
- Fraction of patients with viral load suppression <400 copies/ml [ Time Frame: 12 months after enrolment ]
- Fraction of patients with viral load suppression <50 copies/ml [ Time Frame: 12 months after enrolment ]
- Increment of CD4+ cell count of at least 100 cells/µL [ Time Frame: 12 months after enrolment ]
- Development of ≥1 resistance mutations involving the treatment regimens used in patients with viral load >400 copies/ml [ Time Frame: 12 months after enrolment ]
- Frequency of adverse events and severe adverse events [ Time Frame: Within 12 months ]
- Compliance. [ Time Frame: Within 12 months ]Compliance defined as the actual amount of medicine taken compared to the planned amount for the same treatment period. A pill count is carried out at each visit.
- Incidence of tuberculosis. [ Time Frame: Within 12 months ]
- Death. [ Time Frame: Within 12 months ]Death at 12 month follow-up. Any patient lost to follow-up will be attempted visited at home by a field assistant 1 month after latest visit due. Information on patient death from family or neighbors will be recorded as a mortality event and a verbal autopsy conducted.
- Weight [ Time Frame: Within 12 months ]Increase in body mass index (BMI) and frequency of severe weight loss (>10% of presumed or measured body weight).
- Plasma cytokine levels [ Time Frame: Within 12 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01192035
|Centro de Tratamento Ambulatoria do Hospital Nacional Simão Mendes|
|Principal Investigator:||Sanne Jespersen, MD||Aarhus University Hospital Skejby|
|Study Director:||Alex L Laursen, MD, DMSc||Aarhus University Hospital Skejby|
|Study Director:||Lars Oestergaard, Prof MD DMSc||Aarhus University Hospital Skejby|
|Study Chair:||Christian Wejse, MD, PhD||Aarhus University Hospital Skejby|